DexCom, Inc. DXCM reported strong preliminary results for the fourth quarter and full-year 2024. In response, the company’s ...

DexCom (DXCM) shares rise 6% premarket after setting financial forecast for 2025, projecting 14% revenue growth over 2024 on ...

After spending the past year extending its portfolio of continuous glucose monitors to include people who may not have ...

DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by its strong product portfolio. A ...

Bernstein raised the firm’s price target on DexCom (DXCM) to $89 from $86 and keeps an Outperform rating on the shares as part of a broader research note indicating that the firm is positive on ...

Dexcom (DXCM) currently anticipates total revenue of $4.6B, representing expected growth of approximately 14% over 2024. This outlook ...

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $55.0 to $95.0 for DexCom over the recent three months. In today's trading ...

DexCom (NASDAQ:DXCM – Free Report) had its price objective boosted by Wells Fargo & Company from $90.00 to $94.00 in a report published on Wednesday morning,Benzinga reports.The firm currently ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Insulet Corporation (PODD), has outperformed DexCom. Insulet shares have risen by 36.2% over the past 52 weeks and are up 22.2% on a YTD basis. Despite the stock’s relatively weak price action ...

Dexcom has launched a generative AI platform aimed at providing personalized lifestyle tips to the users of its over-the-counter wearable glucose biosensor. The company said the feature has begun ...